[
  {
    "ts": null,
    "headline": "Regeneron Pharmaceuticals (NasdaqGS:REGN) Reports Q1 2025 Revenue Drop to US$3,029 Million",
    "summary": "Regeneron Pharmaceuticals (NasdaqGS:REGN) recently reported earnings for Q1 2025 with a revenue drop to $3,029 million compared to the prior year, though net income increased, reflecting robust profitability with diluted earnings per share rising to $7.27. The company declared a dividend and executed a significant share repurchase. Despite these positive financial maneuvers, the stock dropped by 8.5% over the last month. Factors like the FDA's complete response letter for EYLEA HD and the...",
    "url": "https://finnhub.io/api/news?id=510f9c2ce6c970fe3807e545a843a4a97f6b680d2eadfbc42ba5b39a901debbc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746897293,
      "headline": "Regeneron Pharmaceuticals (NasdaqGS:REGN) Reports Q1 2025 Revenue Drop to US$3,029 Million",
      "id": 134379573,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Regeneron Pharmaceuticals (NasdaqGS:REGN) recently reported earnings for Q1 2025 with a revenue drop to $3,029 million compared to the prior year, though net income increased, reflecting robust profitability with diluted earnings per share rising to $7.27. The company declared a dividend and executed a significant share repurchase. Despite these positive financial maneuvers, the stock dropped by 8.5% over the last month. Factors like the FDA's complete response letter for EYLEA HD and the...",
      "url": "https://finnhub.io/api/news?id=510f9c2ce6c970fe3807e545a843a4a97f6b680d2eadfbc42ba5b39a901debbc"
    }
  },
  {
    "ts": null,
    "headline": "Is Regeneron Pharmaceuticals, Inc. (REGN) the Worst Blue Chip Stock to Buy?",
    "summary": "We recently published a list of 10 Worst Blue Chip Stocks to Buy. In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against other worst blue chip stocks to buy. As per Niamh Brodie-Machura, Co-Chief Investment Officer at Fidelity International, the effect of tariffs is expected to shift […]",
    "url": "https://finnhub.io/api/news?id=71d77f5a5086bfe0035f6f5f94432ea3adff730f74231cdf30970a7e0c80a35d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746889254,
      "headline": "Is Regeneron Pharmaceuticals, Inc. (REGN) the Worst Blue Chip Stock to Buy?",
      "id": 134379416,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "We recently published a list of 10 Worst Blue Chip Stocks to Buy. In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against other worst blue chip stocks to buy. As per Niamh Brodie-Machura, Co-Chief Investment Officer at Fidelity International, the effect of tariffs is expected to shift […]",
      "url": "https://finnhub.io/api/news?id=71d77f5a5086bfe0035f6f5f94432ea3adff730f74231cdf30970a7e0c80a35d"
    }
  }
]